Third quarter
- Sales of SEK 835 (867) million, 3% growth in local currencies and a 4% decrease in SEK, due to a significant currency impact of -7%. Organic growth in local currencies excluding discontinued business* was 5%.
- Sales per region, in local currencies, were -2% in EMEA, +4% excluding discontinued business, +11% in Americas and +1% in APAC.
- Sales per product group, in local currencies excluding discontinued business, were +7 in Consumables, +8% in Technologies and +3% in Genetics.
- Sales per product group, in local currencies, were +4% in Consumables, +8% in Technologies and 0% in Genetics.
- Gross margin increased to 58.9% (58.6), explained by a favourable product mix despite negative currency impact.
- Earnings before depreciation and amortisation (EBITDA) amounted to SEK 253 (289) million, resulting in an EBITDA margin of 30.3% (33.4), impacted by negative currency effect.
- Operating cash flow amounted to SEK 255 (206) million.
- Net income amounted to SEK 102 (116) million, resulting in earnings per share of SEK 0.75 (0.85).
First nine months
- Sales of SEK 2,548 (2,650) million, 1% growth in local currencies and a 4% decrease in SEK, due to a significant currency impact of -5%. Organic growth in local currencies excluding discontinued business was 4%.
- Sales per region, in local currencies, were +1% in EMEA, +8% excluding discontinued business, +8% in Americas and -5% in APAC.
- Sales per product group, in local currencies excluding discontinued business, were +7% in Consumables, -1% in Technologies and +3% in Genetics.
- Sales per product group, in local currencies, were +4% in Consumables, -2% in Technologies and +1% in Genetics.
- Gross margin decreased to 58.1% (58.6) negatively impacted by currency.
- Earnings before depreciation and amortisation (EBITDA) amounted to SEK 753 (888) million, resulting in an EBITDA margin of 29.5% (33.5), significantly impacted by negative currency effect.
- Operating cash flow amounted to SEK 475 (640) million.
- Net income amounted to SEK 301 (375) million, resulting in earnings per share of SEK 2.23 (2.76).
Gothenburg, October 23, 2025
VITROLIFE AB (publ)
Bronwyn Brophy O'Connor, CEO
* Discontinued business refers to discontinued activities in certain markets in EMEA.
The information was submitted for publication, through the agency of the contact persons set out above, at 23-10-2025 08:00 CET.
Contact:
Amelie Wilson, Investor relations, external corporate communications and executive support, awilson@vitrolife.com
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Vitrolife Group is a global provider of medical devices and genetic testing solutions. Our vision is to enable people to fulfil the dream of having a healthy baby. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. With 1,100 employees worldwide and headquarters in Gothenburg, Sweden, our products and services are available in over 125 countries through our direct presence and a network of distributors. Vitrolife AB (publ) is listed on Nasdaq Stockholm.
Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. E-mail: info@vitrolife.com. Website: www.vitrolifegroup.com.
